Crohn’s-like acute severe colitis associated with Hermansky-Pudlak syndrome: A case report

Paul Girot, Catherine Le Berre, Astrid De Maissin, Marie Freyssinet, Caroline Trang-Poiso, Arnaud Bourreille

Abstract

BACKGROUND
Hermansky-Pudlak syndrome (HPS) is a rare autosomal recessive disorder characterized by oculocutaneous albinism, platelet storage pool deficiency and systemic complications associated with ceroid deposition in the reticuloendothelial system. HPS types 1 and 4 are associated with Crohn’s disease (CD)-like gastrointestinal disorders, such as granulomatous enterocolitis or perianal disease. Cases of colitis can be particularly severe and, before the use of anti-tumor necrosis factor alpha (TNFα) therapy had become common, were reported as showing poor responsiveness to medical treatment.

CASE SUMMARY
We present the case of a 51-year-old albino woman who presented with acute severe colitis that led to the diagnosis of HPS. Histologic findings of biopsy samples showed chronic inflammation with deep ulcerations, and granulomas without caseous necrosis. Molecular genetic analysis confirmed HPS type 1, with a homozygous 27 base-pair deletion in exon 20 of the HPS1 gene. Once the patient’s bleeding diathesis was corrected by platelet transfusion, the granulomatous colitis responded dramatically to a medical treatment regimen that included corticosteroids, azathioprine and infliximab; this regimen is similar to that used in CD treatment. Although it remains unclear if the granulomatous enterocolitis in HPS is due to ceroid deposition or reflects the co-existence of CD and HPS, the fact that this case of HPS-related granulomatous colitis responded to the same therapeutic approach used in CD suggests that this type of colitis may result from HPS patients’ genetic susceptibility to CD.

CONCLUSION
We report a case of severe colitis that led to the diagnosis of HPS, which was...
responsive to azathioprine and infliximab.

**Key words:** Hermansky-Pudlak syndrome; Acute severe colitis; Infliximab; Azathioprine; Inflammatory bowel disease; Case report

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Hermansky-Pudlak syndrome (HPS) is a rare autosomal recessive disorder characterized by oculocutaneous albinism, platelet storage pool deficiency and systemic complications. HPS can be associated with Crohn’s disease (CD)-like gastrointestinal disorders. We present a case of acute severe colitis in an albino woman that led to the diagnosis of HPS. Following bleeding diathesis correction by platelet transfusion, the granulomatous colitis responded dramatically to medical treatment with corticosteroids, azathioprine and infliximab. The fact that this HPS-related granulomatous colitis responded to the same therapeutic approach used in CD suggests that this type of colitis may result from HPS patients’ genetic susceptibility to CD.

**INTRODUCTION**

Hermansky-Pudlak syndrome (HPS) is a rare hereditary autosomal recessive disorder of lysosome-related organelles, characterized by oculocutaneous albinism and storage pool deficiency of platelets with increased bleeding tendency[1]. To date, there are eight subtypes, identified based on the particular genetic mutation responsible for the disorder[2]. Visceral disorders such as pulmonary fibrosis, colitis, cardiomyopathy or renal failure are associated with some but not all subtypes of HPS, with varying degrees of severity. Indeed, HPS types 1 and 4 have been reported as associated with inflammatory bowel disease (IBD)-like disorders of the gastrointestinal tract, such as granulomatous colitis, ileitis, enterocolitis, intestinal fistulization or perianal disease[3-5]. Their clinical, endoscopic and histologic features remain indistinguishable from Crohn’s disease (CD) and ulcerative colitis, suggesting that their physiopathology might be related[3]. We report here a case of HPS type 1 that was diagnosed as a result of acute severe colitis.

**CASE PRESENTATION**

**Chief complaints**
A 51-year-old woman was admitted to the Gastroenterology Intensive Care Unit for hemorrhagic shock secondary to massive rectal bleeding.

**History of present illness**
The patient had lost about 15 kg over the past 5 mo, with recurrent episodes of diffuse abdominal pain that worsened following meals. Bloody diarrhea had started a few days before hospitalization, being intermittently mixed with stool first and progressing to massive rectal bleeding.

**History of past illness, personal and family history**
The patient had very limited medical history, comprised of very low visual acuity only. She reported having been abandoned at birth, and thus not knowing her family.

**Physical examination upon admission**
Initial physical examination demonstrated oculocutaneous albinism with whitish hair, pale skin, horizontal nystagmus and strabismus. Abdominal palpation elicited pain, and perineal examination did not show any anal fissure or fistula. The patient had a slight dyspnea, requiring low flow oxygen therapy, and pulmonary auscultation
revealed bilateral crackles. She also had a severe undernutrition status, with a weight of 32 kg and a body mass index of 13.6 kg/m².

**Laboratory examinations**

Laboratory findings were: hemoglobin of 5.4 g/dL (normal range: 13-18 g/dL), C-reactive protein (commonly known as CRP) of 73 mg/L (normal: < 5 mg/L), and hypoalbuminemia (1.6 g/L; normal range: 3.4-5.4 g/dL). The white blood cell count (8.66 × 10³/µL) and platelet count (268 × 10³/µL) were normal. Bleeding time, activated partial thromboplastin time, and prothrombin time were normal. Stool samples cultures were negative, including for *Clostridium difficile*.

**Imaging examinations**

A computed tomography scan revealed diffuse bilateral interstitial infiltrates consistent with a severe pulmonary fibrosis (Figure 1A), and thickening of the descending/sigmoid colon associated with a transverse and ascending colon mild dilatation. Sigmoidoscopy showed active bleeding colitis, with continuous deep ulcerations (Figure 1B).

**FINAL DIAGNOSIS**

Histologic findings of biopsy samples showed chronic inflammation with deep ulcerations, extending into the muscularis mucosae, and granulomas without caseous necrosis. Molecular genetic analysis confirmed HPS type 1 with a homozygous 27 base-pair deletion in exon 20 of the HPS1 gene (c.2037_2064del).

**TREATMENT**

Intravenous methylprednisolone at a dose of 60 mg daily along with repeated transfusions of red blood cells concentrates was started upon admission. After 48 h, the patient’s CRP had decreased but the substantial rectal bleeding remained, necessitating additional transfusions. Thus, a colon rescue therapy was attempted with an infusion of infliximab at a dose of 5 mg/kg. Because of the HPS suspicion, platelet transfusions were also initiated, despite the normal findings for both platelet count and bleeding time; ultimately, this led to the bleeding ending.

Two weeks later, while the patient was getting better, the second infusion of infliximab was complicated by a severe anaphylactic reaction with bronchospasm that precluded continuance of this treatment. Azathioprine (50 mg daily) was started.

**OUTCOME AND FOLLOW-UP**

Two months later, deep remission was obtained, characterized by the absence of symptoms, normalization of inflammatory biologic markers, and mucosal healing (Figure 2). Unfortunately, the patient was not eligible for lung transplantation due to severe undernutrition and severity of pulmonary fibrosis, and she died of respiratory failure 3 mo later.

**DISCUSSION**

HPS was originally documented in 1959 by two Czechoslovakian physicians, who described two adults with a triad of albinism, hemorrhagic diathesis, and pigmented reticuloendothelial cells. Except in the north-western quarter of the island of Puerto Rico, where HPS affects approximately 1/1800 persons and where approximately 1/22 persons are carriers of the gene, HPS remains extremely rare in the general population, with an estimated incidence between 1/500000 and 1/1000000. HPS type 1 is the most common subtype and is associated with Puerto Rican heritage due to a founder mutation in this population. Diagnosis of HPS can be clinically suspected and is confirmed by molecular genetic analysis that allows classification into a particular HPS subtype (HPS 1-8).

Rarity of this syndrome can lead to delayed diagnosis and underlies the general lack of knowledge about its pathology, as was the case with our patient. HPS includes a platelet storage pool deficiency characterized by abnormally low contents of platelet α granules and/or δ granules that results in a bleeding diathesis; this can be accompanied by normal findings in the usual blood tests, such as platelet count and
Granulomatous colitis was described as a complication of HPS for the first time in 1980[8]. Since then, many cases of inflammatory bowel disorders have been described, including those of colitis, enterocolitis or perianal disease[8,9,10]. These gastrointestinal complications are associated with HPS 1 and HPS 4 subtypes, occur in 20%-30% of the cases[3,4], and have been the cause of death in 9% of the deceased HPS patients in Puerto Rico[6]. The granulomatous colitis associated with HPS shares features with both ulcerative colitis and CD. In fact, clinical presentation and friable erythematous mucosa with ulcerations from rectum to cecum are suggestive of ulcerative colitis[10-12], but they present pathologic findings consistent with CD and can be associated with perianal and perirectal disease resembling the typical anorectal findings often seen in patients with CD[4,9,12].

Although HPS is caused by a single-gene defect that alters endosome trafficking and in spite of the fact that the proteins encoded by HPS1 and HPS4 genes are identified, the pathogenesis of the granulomatous colitis found in patients with HPS remains unclear. Moreover, it is also unclear if colitis associated with HPS is part of the syndrome, or if it represents an independent but associated process, such as CD[11]. Initially, it was suggested that granulomatous colitis of HPS results from the accumulation of ceroid lipofuscin in intestinal macrophages because of the defects in synthesis, processing and trafficking of lysosome-related organelles. As there is no degradative pathway for ceroid, this accumulation was supposed to induce macrophages’ burst and a release of enzymes and cytokines, resulting in an inflammatory response[3,4,8,11]. But, some patients have had granulomatous colitis without ceroid pigments[10] and it has been noted that granulomas are not formed in relation to deposits of the ceroid-like pigments[9].

Thus, an alternative hypothesis has been proposed which is based on recent advances in the understanding of the pathophysiology of both HPS and CD[12]. HPS1 and HPS4 form a protein complex called the Biogenesis of Lysosome-related Organelles Complex 3 (BLOC-3), that triggers local activation of Rab GTP-ase proteins, called Rab32 and Rab38[13]. These small GTP-ases interact and co-locate with the protein LRRK2 to transport vesicles and recycling endosomes, and play an important role in the biogenesis and traffic of melanosomes and lysosomes. This system is disordered in HPS, accounting for the characteristic albinism[14], and LRRK2 has been recently identified by genome-wide association studies as a susceptibility gene for CD[15]. Therefore, this hypothesis suggests that granulomatous colitis in HPS results from genetic susceptibility to classical IBD.

In this case, medical treatment based on corticosteroids, azathioprine and one infusion of anti-tumor necrosis factor alpha (TNFα) therapy resulted in rapid improvement of clinical symptoms and endoscopic lesions. Among the nine published cases of HPS patients who received anti-TNFα therapy for a digestive complication[9-12], five had a good response, three necessitated surgical treatment, and the last one did not have any response to the anti-TNFα therapy but was improved by tacrolimus then vedolizumab[12]. The fact that therapeutic approaches similar to those for CD can also be effective in patients with HPS digestive complications reinforces the idea that HPS may be linked to CD. Further research is needed to determine the cause of the granulomatous enterocolitis of HPS, but all information gathered
CONCLUSION

We report herein the case of acute severe colitis in an albino woman, that led to the diagnosis of HPS. This granulomatous colitis responded dramatically to a therapeutic approach based on corticosteroids, azathioprine and infliximab, which is similar to the results seen with this regimen in IBD treatment.

REFERENCES

1. Hermansky F, Pudlak P. Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow: report of two cases with histochemical studies. Blood 1959; 14: 162-169 [PMID: 13618373]
2. Wei ML. Hermansky-Pudlak syndrome: a disease of protein trafficking and organelle function. Pigment Cell Res 2006; 19: 19-42 [PMID: 16420244 DOI: 10.1111/j.1600-0749.2005.00289.x]
3. Hussain N, Quezado M, Huizing M, Geho D, White JG, Gahl W, Mannon P. Intestinal disease in Hermansky-Pudlak syndrome: occurrence of colitis and relation to genotype. Clin Gastroenterol Hepatol 2006; 4: 73-80 [PMID: 16431908 DOI: 10.1016/S1542-3565(05)00858-X]
4. Hazan D, Seward S, Stock H, Zisman S, Gabriel K, Harper N, Bauer JJ. Crohn's-like colitis, enterocolitis and perianal disease in Hermansky-Pudlak syndrome. Colorectal Dis 2006; 8: 539-543 [PMID: 16919103 DOI: 10.1111/j.1463-1318.2006.00146.x]
5. Mora AJ, Wolfsohn DM. The management of gastrointestinal disease in Hermansky-Pudlak syndrome. J Clin Gastroenterol 2011; 45: 700-702 [PMID: 21085008 DOI: 10.1097/MCG.0b013e31825d742]
6. Witkop CJ. Nihutz Babcock M, Rao GH, Gaudier F, Summers CG, Shanahan F, Harmon KR, Townsend D, Sedano HO, King RA. Albinism and Hermansky-Pudlak syndrome in Puerto Rico. Bol Assoc Med P R 1990; 82: 333-339 [PMID: 2260223 DOI: 10.1111/j.1463-1318.2006.01046.x]
7. Schinella RA, Greco MA, Cobert BL, Denmark LW, Cox RP. Hermansky-Pudlak syndrome with granulomatous colitis. Am J Gastroenterol 2000; 95: 20-23 [PMID: 10358669 DOI: 10.1111/j.1572-0241.2000.00146.x]
8. Erzin Y, Cosgun S, Doğrucały A, Tasyurekli M, Erdamar S, Tunçer M. Complicated granulomatous colitis in a patient with Hermansky-Pudlak syndrome, successfully treated with infliximab. Acta Gastroenterol Belg 2006; 69: 213-216 [PMID: 16929618]
9. Kouklakis G, Efermiou EI, Papageorgiou MS, Pavlidou E, Manolas KJ, Liratzopoulos N. Complicated Crohn's-like colitis, associated with Hermansky-Pudlak syndrome, treated with Infliximab: a case report and brief review of the literature. J Med Case Rep 2007; 1: 176 [PMID: 18067668 DOI: 10.1186/1752-1947-1-176]
10. Grucela AL, Patel P, Goldstein E, Palmon R, Sachar DB, Steinshagen RM. Granulomatous enterocolitis associated with Hermansky-Pudlak syndrome. Am J Gastroenterol 2006; 101: 2090-2095 [PMID: 16848425 DOI: 10.1111/j.1572-0241.2006.00733.x]
11. Sofia MA, Sakaraba A, Rubin DT. Two Complex Cases of Hermansky-Pudlak Syndrome Highlight a Potential Biologic Explanation for an Associated Crohn's Disease Phenotype. ACG Case Rep J 2017; 4: e14 [PMID: 28144619 DOI: 10.14309/crj.2017.14]
12. Gerondopoulos A, Langenmeyer L, Liang JR, Linford A, Barr FA. BLOC-3 mutated in Hermansky-Pudlak syndrome is a Rab32/38 guanine nucleotide exchange factor. Curr Biol 2012; 22: 2135-2139 [PMID: 23084991 DOI: 10.1016/j.cub.2012.09.020]
13. Segal AW. Making sense of the cause of Crohn's - a new look at an old disease. F1000Res 2016; 5: 2510 [PMID: 28105308 DOI: 10.12688/f1000research.9689.2]
14. Derkinderen P, Neefeld M. Crohn's and Parkinson disease: is LRRK2 lurking around the corner? Nat Rev Gastroenterol Hepatol 2018; 15: 330-331 [PMID: 28664341 DOI: 10.1038/nrgastro.2018.6]
